Novartis is developing the new combination for asthma treatment which will be given once daily. It involves the combination of indacaterol acetate /glycopyrronium bromide, which imparts bronchodilation effect along with momentasone furoate through dose controlling Breezhaler.
A favorable tolerable and safety profile is demonstrated by IND/GLY/MF in phase II studies. The combination was observed to improvise the lung functioning in comparison to placebo. Also, time of administration has no effect on its functioning.
This new inhaled combination is found to be superior in comparison to LABA/ICS long-acting beta agonist/inhaled corticosteroid. No severe adverse effects were observed during the treatment period. The phase III clinical trials of IND/GLY/MF are ongoing.
About one-third asthmatic patients are experiencing exacerbations despite the accessibility of several treatments for asthma. Breezhaler is already established to be used in COPD. If the new combination will get the approval, then this would be beneficial for patients who have uncontrolled asthma.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like